Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Magnetic Resonance Spectroscopy 3Specimen Handling 2Papillomavirus Vaccines 2Lenalidomide 2Immune Checkpoint Inhibitors 2Imatinib Mesylate 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Dexamethasone 2venetoclax 1trametinib 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1semaglutide 1ruxolitinib 1rozanolixizumab 1rasburicase 1radium Ra 223 dichloride 1pyrotinib 1pirtobrutinib 1oxycodone-acetaminophen 1obinutuzumab 1nirogacestat 1nilotinib 1ixazomib 1idelalisib 1human papillomavirus vaccine, L1 type 16, 18 1fluciclovine F-18 1darolutamide 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × idelalisib × 30 days × Clear all
NCT07218341 2026-05-22

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Eli Lilly and Company

Phase 4 Recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡